Table 2.

Prevalence of AR-FL and AR-V7 in large RNA-Seq data sets from patients with primary or metastatic prostate cancer.

505 primary prostate cancer samples (TCGA)
AR-FL positive	98% (496 in 505) samples
AR-V7 positive	29% (147 in 505) samples
AR-FL reads range	0–364 (mean: 55.9)
AR-V7 reads range	0–72 (mean: 3.4)

98 mCRPC samples (SU2C)
AR-FL positive	97% (95 in 98) samples
AR-V7 positive	79% (77 in 98) samples
AR-FL reads range	0–23321 (mean: 3771.5)
AR-V7 reads range	0–852 (mean: 82.3)

Expression of AR-FL and AR-V7 was determined in primary prostate cancer samples (TCGA, n = 505) and mCRPC samples (SU2C, n = 98) by RNA-Seq data analysis using specific exon mapping reads as described in “Methods”. Transcript prevalence was calculated in both datasets and is displayed along with transcript expression range and mean.